Skip Nav Destination
Blinatumomab for MRD+ B-ALL: the evidence strengthens
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis
Issue Archive
April 5 2018
In this Issue
Table of Contents
CLINICAL TRIALS AND OBSERVATIONS
Blinatumomab for MRD+ B-ALL: the evidence strengthens
Clinical Trials & Observations
BLOOD SPOTLIGHT
REVIEW ARTICLE
CLINICAL TRIALS AND OBSERVATIONS
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
Clinical Trials & Observations
Nicola Gökbuget,Hervé Dombret,Massimiliano Bonifacio,Albrecht Reichle,Carlos Graux,Christoph Faul,Helmut Diedrich,Max S. Topp,Monika Brüggemann,Heinz-August Horst,Violaine Havelange,Julia Stieglmaier,Hendrik Wessels,Vincent Haddad,Jonathan E. Benjamin,Gerhard Zugmaier,Dirk Nagorsen,Ralf C. Bargou
HEMATOPOIESIS AND STEM CELLS
hsa-mir183/EGR1–mediated regulation of E2F1 is required for CML stem/progenitor cell survival
Francesca Pellicano,Laura Park,Lisa E. M. Hopcroft,Mansi M. Shah,Lorna Jackson,Mary T. Scott,Cassie J. Clarke,Amy Sinclair,Sheela A. Abraham,Alan Hair,G. Vignir Helgason,Mark Aspinall-O’Dea,Ravi Bhatia,Gustavo Leone,Kamil R. Kranc,Anthony D. Whetton,Tessa L. Holyoake
IMMUNOBIOLOGY AND IMMUNOTHERAPY
BAFF and CD4+ T cells are major survival factors for long-lived splenic plasma cells in a B-cell–depletion context
Lan-Huong Thai,Simon Le Gallou,Ailsa Robbins,Etienne Crickx,Tatiana Fadeev,Zhicheng Zhou,Nicolas Cagnard,Jérôme Mégret,Christine Bole,Jean-Claude Weill,Claude-Agnès Reynaud,Matthieu Mahévas
LYMPHOID NEOPLASIA
Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis
Clinical Trials & Observations
Efstathios Kastritis,Ioannis Papassotiriou,Giampaolo Merlini,Paolo Milani,Evangelos Terpos,Marco Basset,Athanasios Akalestos,Francesca Russo,Erasmia Psimenou,Filia Apostolakou,Maria Roussou,Maria Gavriatopoulou,Evangelos Eleutherakis-Papaiakovou,Despina Fotiou,Dimitrios C. Ziogas,Elektra Papadopoulou,Constantinos Pamboucas,Meletios A. Dimopoulos,Giovanni Palladini
MYELOID NEOPLASIA
Integrated molecular profiling of juvenile myelomonocytic leukemia
Norihiro Murakami,Yusuke Okuno,Kenichi Yoshida,Yuichi Shiraishi,Genta Nagae,Kyogo Suzuki,Atsushi Narita,Hirotoshi Sakaguchi,Nozomu Kawashima,Xinan Wang,Yinyan Xu,Kenichi Chiba,Hiroko Tanaka,Asahito Hama,Masashi Sanada,Masafumi Ito,Masashi Hirayama,Arata Watanabe,Toshihide Ueno,Seiji Kojima,Hiroyuki Aburatani,Hiroyuki Mano,Satoru Miyano,Seishi Ogawa,Yoshiyuki Takahashi,Hideki Muramatsu
PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS
RED CELLS, IRON, AND ERYTHROPOIESIS
TRANSFUSION MEDICINE
LETTERS TO BLOOD
Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia
Marina Wierz,Sandrine Pierson,Léa Guyonnet,Elodie Viry,Audrey Lequeux,Anaïs Oudin,Simone P. Niclou,Markus Ollert,Guy Berchem,Bassam Janji,Coralie Guérin,Jerome Paggetti,Etienne Moussay
BLOOD WORK
-
Cover Image
Cover Image
Peripheral blood from a patient with juvenile myelomonocytic leukemia (JMML) harboring RANBP2-ALK demonstrates dysplastic monocytes similar to those observed in patients with JMML harboring canonical RAS mutations (May-Giemsa stain; original magnification ×1000). See the article by Murakami et al on page 1576.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals